Page last updated: 2024-10-15

tegaserod

Description

tegaserod: a nonbenzamide 5-hydroxytryptamine(4) agonist; used in treatment of irritable bowel syndrome; marketing suspended 2007 in US due to higher incidence of MI, stroke, and unstable angina; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID135409453
CHEMBL ID76370
CHEBI ID51043
CHEBI ID94540
SCHEMBL ID16464
SCHEMBL ID8229619
SCHEMBL ID8194377
SCHEMBL ID15654154
MeSH IDM0274190

Synonyms (77)

Synonym
AC-4564
CHEMBL76370 ,
LS-14526
CHEBI:51043 ,
tegaserodum
2-[(5-methoxy-2,3-dihydro-1h-indol-3-yl)methylene]-n-pentylhydrazinecarboximidamide
unii-458vc51857
458vc51857 ,
BRD-K88743730-001-01-0
zelmac
sdz-htf-919
BSPBIO_003270
tegaserod (usan/inn)
145158-71-0
D06056
SPECTRUM5_001691
BSPBIO_002344
MLS001401406 ,
smr000471618
1-(((5-methoxyindol-3-yl)methylene)amino)-3-pentylguanidine
tegaserod
DB01079
NCGC00095192-01
NCGC00095192-02
hydrazinecarboximidamide, 2-((5-methoxy-1h-indol-3-yl)methylene)-n-pentyl-
htf 919
SPECTRUM1505823
NCGC00095192-04
NCGC00095192-03
bdbm50240618
(2e)-2-[(5-methoxy-1h-indol-3-yl)methylene]-n-pentylhydrazinecarboximidamide
HMS1922J08
cas-145158-71-0
tox21_111481
dtxcid4025955
dtxsid6045955 ,
1044642-88-7
tegaserod [vandf]
tegaserod [who-dd]
tegaserod [usan]
hydrazinecarboximidamide, 2-((5-methoxy-1h-indol-3-yl)methylene)-n-pentyl-, (2e)-
tegaserod [inn]
1-[[(5-methoxyindol-3-yl)methylene]amino]-3-pentylguanidine
tegaserod [mi]
tegaserod [ema epar]
AM84414
AKOS015913793
AB01209613-03
AB01209613-01
SCHEMBL16464
NCGC00095192-05
tox21_111481_1
(z)-but-2-enedioic acid;1-[[(z)-(5-methoxyindol-3-ylidene)methyl]amino]-2-pentyl-guanidine
2-amyl-1-[[(z)-(5-methoxyindol-3-ylidene)methyl]amino]guanidine;maleic acid
cid_6918369
bdbm79022
(z)-but-2-enedioic acid;1-[[(z)-(5-methoxyindol-3-ylidene)methyl]amino]-2-pentylguanidine
(z)-2-butenedioic acid;1-[[(z)-(5-methoxy-3-indolylidene)methyl]amino]-2-pentylguanidine
SCHEMBL8229619
SCHEMBL8194377
SCHEMBL15654154
2-((5-methoxy-1h-indol-3-yl)methylene)-n-pentylhydrazinecarboximidamide
AB01563050_01
CHEBI:94540
J-008063
NCGC00095192-11
A909403
NCGC00095192-08
HY-14153
CS-0003233
a06ax06
2-((5-methoxy-2,3-dihydro-1h-indol-3-yl)methylene)-n-pentylhydrazinecarboximidamide
EN300-117255
n'-{[(5-methoxy-1h-indol-3-yl)methylidene]amino}-n-pentylguanidine
Z1501480423
n'-[(e)-[(5-methoxy-1h-indol-3-yl)methylidene]amino]-n-pentylguanidine
(e)-2-((5-methoxy-1h-indol-3-yl)methylene)-n-pentylhydrazine-1-carboximidamide

Research Excerpts

Overview

Tegaserod is a first-in class selective serotonin 4 receptor agonist approved for the treatment of irritable bowel syndrome. Tegaserod 6 mg b.i.d. is an effective, safe and well-tolerated treatment in patients suffering from IBS without diarrhoea as primary bowel symptom.

ExcerptReference
"Tegaserod (Zelnorm®) is a 5-hydroxytryptamine (serotonin) type 4 receptor agonist for the treatment of hypomotility disorders of the lower gastrointestinal tract associated with the irritable bowel syndrome with constipation (IBS-C)."( Tegaserod for the Treatment of Irritable Bowel Syndrome.
Bortolami, M; Costi, R; De Leo, A; De Vita, D; Di Santo, R; Madia, VN; Messore, A; Pindinello, I; Saccoliti, F; Scipione, L; Tudino, V, 2020
)
"Tegaserod is a 5-HT"( Re-evaluation of the Cardiovascular Safety Profile of Tegaserod: A Review of the Clinical Data.
Brenner, DM; Chey, WD; Lacy, BE, 2022
)
"Tegaserod is a 5-hydroxytryptamine type 4 (5-HT"( Effect of the 5-HT
Coupar, IM; Irving, HR; Nedi, T; White, PJ, 2018
)
"Tegaserod is a first-in class selective serotonin 4 receptor agonist approved for the treatment of irritable bowel syndrome. "( Lack of association of tegaserod with adverse cardiovascular outcomes in a matched case-control study.
Anderson, JL; Bair, TL; Carlquist, JF; Horne, BD; May, HT; Muhlestein, JB, 2009
)
"Tegaserod is a selective partial agonist acting on serotonergic type 4 receptors (5-HT(4)). "( Tegaserod: a new 5-HT(4) agonist in the treatment of irritable bowel syndrome.
Corsetti, M; Tack, J, 2002
)
"Tegaserod is a 5-hydroxytryptamine-4 receptor partial agonist. "( Long-term safety of tegaserod in patients with constipation-predominant irritable bowel syndrome.
Earnest, DL; Langaker, KE; Nault, B; Otten, MH; Pecher, E; Pruitt, RE; Rojavin, MA; Snape, WJ; Tougas, G, 2002
)
"Tegaserod 6 mg b.i.d. is an effective, safe and well-tolerated treatment in patients suffering from IBS without diarrhoea as primary bowel symptom."( A double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndrome.
Bang, C; Elsborg, L; Holme, I; Jones, J; Nyhlin, H; Rüegg, P; Silvennoinen, J; Wagner, A, 2004
)
"Tegaserod is a new partial agonist of serotonin 5-HT4 receptors specifically developed for the treatment of nondiarrhoeal forms of irritable bowel syndrome (IBS). "( Benefit-risk assessment of tegaserod in irritable bowel syndrome.
Lea, R; Whorwell, PJ, 2004
)
"Tegaserod maleate is a relatively new 5-HT4 receptor agonist with moderate affinity for the 5-HT1 receptor."( Tegaserod-induced myocardial infarction: case report and hypothesis.
Busti, AJ; Cryer, B; Murillo, JR, 2004
)
"Tegaserod is a 5-HT(4) receptor partial agonist that increases peristaltic activity of the intestinal tract. "( Tegaserod does not alter fasting or meal-induced biliary tract motility.
Beglinger, C; Chey, WD; Dogra, A; Earnest, DL; Fisher, RS; Lembo, A; Luo, D; Novick, J; O'Kane, P; Rueegg, P; Shi, V; Thistle, J, 2004
)
"1 Tegaserod (Zelnorm) is a potent 5-hydroxytryptamine4 (5-HT4) receptor agonist with clinical efficacy in disorders associated with reduced gastrointestinal motility and transit. "( The 5-HT4 receptor agonist, tegaserod, is a potent 5-HT2B receptor antagonist in vitro and in vivo.
Armstrong, SR; Beattie, DT; Humphrey, PP; Mai, N; Marquess, D; McCullough, JL; Pulido-Rios, T; Richardson, C; Sandlund, C; Smith, JA; Vickery, RG, 2004
)
"Tegaserod is a drug in a new class of compounds called aminoguanidine indoles and is structurally similar to serotonin (5-HT) with modifications that make the drug selective for the 5-HT(4) receptor. "( Review of tegaserod in the treatment of irritable bowel syndrome.
Berrada, D; Lembo, A; Patel, S, 2004
)
"Tegaserod is a promotility agent with proven efficacy and safety in patients with irritable bowel syndrome with constipation."( Effect of tegaserod on work and daily activity in irritable bowel syndrome with constipation.
Barghout, V; McBurney, CR; Niecko, TE; Reilly, MC, 2005
)
"Tegaserod is a novel selective serotonin receptor type-4 (5-HT(4)) partial agonist that stimulates gastrointestinal (GI) motility. "( Effect of tegaserod on gut transit in male and female subjects.
Beglinger, C; Degen, L; Petrig, C; Schroller, S; Studer, D, 2005
)
"Tegaserod is a 5-HT(4) receptor partial agonist approved for the treatment of irritable bowel syndrome in women with constipation and in both men and women with chronic constipation. "( Activation of peripheral 5-HT receptors attenuates colonic sensitivity to intraluminal distension.
Crowell, MD; Dennis, E; Greenwood-Van Meerveld, B; Hicks, G; Venkova, K, 2006
)
"Tegaserod is a partial 5-hydroxytryptamine 4 receptor agonist with prokinetic effects on the gastrointestinal tract, its effects on oesophageal function are unknown."( The effects of tegaserod on oesophageal function and bolus transport in healthy volunteers: studies using concurrent high-resolution manometry and videofluoroscopy.
Fox, M; Fried, M; Menne, D; Schwizer, W; Stutz, B, 2006
)
"Tegaserod is a 5-hydroxytryptamine type 4 agonist that stimulates gastrointestinal motility and is approved for the treatment of chronic idiopathic constipation."( Tegaserod in constipation associated with Parkinson disease.
Morgan, JC; Sethi, KD,
)
"Tegaserod is a novel drug for the treatment of constipation-predominant irritable bowel syndrome. "( Tegaserod inhibits the serotonin transporter SERT.
Blakely, RD; Fried, M; Ismair, MG; Kullak-Ublick, GA; Vavricka, SR, 2007
)
"Tegaserod is an effective alternative prokinetic agent for ICU patients with a safer side-effect profile. "( A clinical audit of the efficacy of tegaserod as a prokinetic agent in the intensive care unit.
Collins, SJ; Fowler, S; Goldrick, PB; Stephens, DP; Thomas, JH, 2007
)
"Tegaserod (HTF 919) is a new drug being developed for gastrointestinal motility disorders. "( Comparison of tegaserod (HTF 919) and its main human metabolite with cisapride and erythromycin on cardiac repolarization in the isolated rabbit heart.
Drici, MD; Ebert, SN; Liu, XK; Rodriguez, I; Wang, WX; Whitfield, BH; Woosley, RL, 1999
)
"Tegaserod is a serotonin (5-hydroxytryptamine; 5-HT) receptor partial agonist which has been investigated for the treatment of irritable bowel syndrome (IBS). "( Tegaserod.
Perry, CM; Scott, LJ, 1999
)
"Tegaserod (HTF 919) is a selective 5-HT4 receptor partial agonist in development for the treatment of irritable bowel syndrome."( The pharmacokinetics of the novel promotile drug, tegaserod, are similar in healthy subjects-male and female, elderly and young.
Appel-Dingemanse, S; Campestrini, J; Horowitz, A; McLeod, J; Osborne, S, 2001
)
"Tegaserod is a selective 5-HT(4) receptor partial agonist with promotile activity in the gastrointestinal tract. "( In vitro metabolism of tegaserod in human liver and intestine: assessment of drug interactions.
Dannecker, R; Fischer, V; Heitz, F; Tynes, R; Vickers, AE; Zollinger, M, 2001
)
"Tegaserod (HTF 919) is a highly specific 5-HT4 receptor partial agonist that exhibits promotile activity throughout the gastrointestinal tract and is under development for the treatment of functional gastrointestinal motility disorders. "( The effects of tegaserod (HTF 919) on the pharmacokinetics and pharmacodynamics of digoxin in healthy subjects.
Appel-Dingemanse, S; Horowitz, A; Hubert, M; Ledford, PC; McLeod, JF; Osborne, S; Zhou, H, 2001
)
"Tegaserod is a medication that has been shown to be of benefit in women with irritable bowel syndrome (IBS) associated with abdominal pain, bloating, and constipation. "( Tegaserod: a new 5-HT4 agonist.
Lacy, BE; Yu, S, 2002
)
"Tegaserod is a novel selective serotonin receptor type-4 (5-HT4) partial agonist with structural similarity to 5-HT Tegaserod stimulates small bowel and colonic motility and helps to normalise GI function."( Tegaserod: a novel, selective 5-HT4 receptor partial agonist for irritable bowel syndrome.
Beglinger, C,
)
"Tegaserod is a selective serotonin (5-HT4) receptor partial agonist effective in providing relief from abdominal pain, bloating, and constipation in patients with irritable bowel syndrome. "( Safety and tolerability of tegaserod in patients with irritable bowel syndrome and diarrhea symptoms.
Fidelholtz, J; Lefkowitz, M; Rawls, J; Rüegg, P; Shi, Y; Smith, W; Zack, A, 2002
)

Effects

Tegaserod has a marginal effect on the quality of colonoscopy preparation when used as an adjuvant to PEG-E. It has a stimulatory effect on gastrointestinal (GI) motility that has been demonstrated in animal studies and in healthy adults. Tegaserod is well tolerated during continuous long-term treatment in patients with CC.

Tegaserod has been shown to be an effective therapy for the multiple symptoms of irritable bowel syndrome (IBS) in Western populations. It has been safely employed in clinical trials where it has demonstrated efficacy in normalizing intestinal function.

ExcerptReference
"Tegaserod has a marginal effect on the quality of colonoscopy preparation when used as an adjuvant to PEG-E. "( A randomized, controlled, double-blind trial of the adjunct use of tegaserod in whole-dose or split-dose polyethylene glycol electrolyte solution for colonoscopy preparation.
Abdul-Baki, H; Azar, C; Barada, KA; El Zahabi, L; Elhajj, II; Hashash, JG; Mourad, FH; Sharara, AI, 2008
)
"Tegaserod has a stimulatory effect on gastrointestinal (GI) motility that has been demonstrated in animal studies and in healthy adults."( Review of tegaserod in the treatment of irritable bowel syndrome.
Berrada, D; Lembo, A; Patel, S, 2004
)
"Tegaserod has a favorable safety profile and is well tolerated during continuous long-term treatment in patients with CC."( Safety, tolerability, and efficacy of tegaserod over 13 months in patients with chronic constipation.
Dunger-Baldauf, C; Earnest, DL; Kamm, MA; Müller-Lissner, S; Musoglu, A; Shetzline, MA, 2006
)
"Tegaserod has a favorable safety and tolerability profile for treating non-D-IBS and IBS-C in men and women in the Asia-Pacific region. "( Safety, tolerability and satisfaction with tegaserod therapy in Asia-Pacific patients with irritable bowel syndrome with constipation.
Fock, KM; Wagner, A, 2007
)
"Tegaserod has been shown to be an effective therapy for the multiple symptoms of irritable bowel syndrome (IBS) in Western populations. "( An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome.
Bak, YT; Chang, FY; Gwee, KA; Jones, J; Kellow, J; Lee, OY; Mazlam, MZ; Thongsawat, S; Wagner, A; Yuen, H, 2003
)
"Tegaserod has been shown to be an effective therapy for the multiple symptoms of irritable bowel syndrome (IBS) in Western and Asia-Pacific populations. "( A double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndrome.
Bang, C; Elsborg, L; Holme, I; Jones, J; Nyhlin, H; Rüegg, P; Silvennoinen, J; Wagner, A, 2004
)
"Tegaserod has been assessed in a number of international multicentre trials and its use leads to an improvement in abdominal pain and bowel dysfunction as well as global well-being, at the expense of remarkably few adverse effects."( Benefit-risk assessment of tegaserod in irritable bowel syndrome.
Lea, R; Whorwell, PJ, 2004
)
"Tegaserod has been safely employed in clinical trials where it has demonstrated efficacy in normalizing intestinal function, thereby improving irritable bowel syndrome symptoms."( Tegaserod: a serotonin 5-HT4 receptor agonist for treatment of constipation-predominant irritable bowel syndrome.
Cole, P; Rabasseda, X, 2004
)
"Tegaserod has been shown to be effective in chronic constipation in Western population. "( Efficacy of tegaserod for functional constipation in Chinese subjects: a randomized double-blind controlled trial in a single centre.
Hu, WH; Lam, SK; Leung, G; Mo Hui, W; On Chan, AO; Wong, BC, 2007
)
"Tegaserod has been found to inhibit cytochrome P-450 (CYP) 1A2, for which theophylline is a prototype substrate."( Tegaserod coadministration does not alter the pharmacokinetics of theophylline in healthy subjects.
Appel-Dingemanse, S; Khalilieh, S; Lasseter, K; McLeod, JF; Osborne, S; Pommier, F; Svendsen, K; Zhou, H, 2001
)
"Tegaserod has been shown to modulate both gastrointestinal motility and visceral sensitivity."( Tegaserod: a new 5-HT4 agonist.
Lacy, BE; Yu, S, 2002
)

Actions

Tegaserod may enhance upper gut transit, but, its prokinetic effects on antral/small bowel motility and how this compares with erythromycin is unknown. Tegaserod did not increase evacuation in individuals without physiologic gas retention.

ExcerptReference
"Tegaserod may enhance upper gut transit, but, its prokinetic effects on antral/small bowel motility and how this compares with erythromycin is unknown. "( Effects of tegaserod and erythromycin in upper gut dysmotility: a comparative study.
Attaluri, A; Hashmi, SM; Nasr, I; Rao, SS; Summers, R,
)
"Tegaserod did not increase evacuation in individuals without physiologic gas retention."( Modulation of intestinal gas dynamics in healthy human volunteers by the 5-HT receptor agonist tegaserod.
Coleski, R; Hasler, WL; Owyang, C, 2006
)
"Tegaserod did not alter lower oesophageal sphincter pressure, but had significant effects on peristaltic function. "( The effects of tegaserod on oesophageal function and bolus transport in healthy volunteers: studies using concurrent high-resolution manometry and videofluoroscopy.
Fox, M; Fried, M; Menne, D; Schwizer, W; Stutz, B, 2006
)
"Tegaserod does not cause adverse pharmacodynamic effects, is absorbed rapidly after oral administration and distributes widely into tissues."( Review article: tegaserod.
Camilleri, M, 2001
)

Treatment

Tegaserod-treated patients in RCTs have not demonstrated significant prolongation of the QTc interval or cardiac arrhythmias. Tegaserod treatment had no significant effect on plasma CCK concentration in response to the test meal.

ExcerptReference
"Mean tegaserod treatment duration in the two studies was 236 and 222 days. "( Long-term tegaserod treatment for dysmotility-like functional dyspepsia: results of two identical 1-year cohort studies.
Chey, WD; Earnest, DL; Howden, CW; Ligozio, G; Tack, J, 2010
)
"Tegaserod-treated patients in RCTs have not demonstrated significant prolongation of the QTc interval or cardiac arrhythmias compared with placebo-treated patients."( Safety profile of tegaserod, a 5-HT4 receptor agonist, for the treatment of irritable bowel syndrome.
Hasler, WL; Schoenfeld, P, 2004
)
"Tegaserod treatment had no significant effect on plasma CCK concentration in response to the test meal."( Tegaserod does not alter fasting or meal-induced biliary tract motility.
Beglinger, C; Chey, WD; Dogra, A; Earnest, DL; Fisher, RS; Lembo, A; Luo, D; Novick, J; O'Kane, P; Rueegg, P; Shi, V; Thistle, J, 2004
)
"Tegaserod-treated patients in randomized controlled trials did not demonstrate significant prolongation of the QTc interval or cardiac arrhythmias compared with placebo-treated patients."( Review article: the safety profile of tegaserod.
Schoenfeld, P, 2004
)
"Tegaserod treatment, which did not affect cholinergic contractions of tissues from low cholesterol fed animals, abrogated the increase caused by the high cholesterol diet."( Increased cholinergic contractions of jejunal smooth muscle caused by a high cholesterol diet are prevented by the 5-HT4 agonist--tegaserod.
Mathison, R; Shaffer, E, 2006
)
"Tegaserod treatment or enriched cholesterol diet, alone or combination, did not alter body or liver weights."( Effects of tegaserod on bile composition and hepatic secretion in Richardson ground squirrels on an enriched cholesterol diet.
Earnest, D; Mathison, R; Pfannkuche, HJ; Shaffer, E, 2006
)
"Tegaserod treatment results in increased enterohepatic cycling and lowers cholesterol saturation in the bile of cholesterol-fed animals. "( Effects of tegaserod on bile composition and hepatic secretion in Richardson ground squirrels on an enriched cholesterol diet.
Earnest, D; Mathison, R; Pfannkuche, HJ; Shaffer, E, 2006
)
"Tegaserod treatment resulted in a rapid and significant increase from baseline in the adjusted mean number of CSBMs per week over wk 1-4 compared with placebo (1.39 vs 0.91, P = 0.0002)."( A randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of tegaserod in patients from China with chronic constipation.
diTommaso, S; Huang, J; Ke, MY; Lin, SR; Luo, JY; Walter, V; Wang, JY; Yuan, YZ, 2007
)
"Tegaserod treatment improved multiple symptoms of CC and was associated with a favorable safety profile."( A randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of tegaserod in patients from China with chronic constipation.
diTommaso, S; Huang, J; Ke, MY; Lin, SR; Luo, JY; Walter, V; Wang, JY; Yuan, YZ, 2007
)
"Treatment with tegaserod seems also to exert a protective effect in inflamed colons, reducing the severity of colitis in animal models."( Tegaserod for the Treatment of Irritable Bowel Syndrome.
Bortolami, M; Costi, R; De Leo, A; De Vita, D; Di Santo, R; Madia, VN; Messore, A; Pindinello, I; Saccoliti, F; Scipione, L; Tudino, V, 2020
)

Toxicity

Tegaserod is safe for women <65 years of age with irritable bowel syndrome with constipation, no history of cardiovascular ischemic events, and ≤1 cardiovascular risk factor. About 10% of the patients in the tegaserod group experienced an adverse event compared to 6% in the placebo group.

ExcerptReference
" Adverse events were recorded."( Safety and tolerability of tegaserod in patients with irritable bowel syndrome and diarrhea symptoms.
Fidelholtz, J; Lefkowitz, M; Rawls, J; Rüegg, P; Shi, Y; Smith, W; Zack, A, 2002
)
"Diarrhea, abdominal pain, headache, flatulence, and fatigue were the most frequently reported adverse events."( Safety and tolerability of tegaserod in patients with irritable bowel syndrome and diarrhea symptoms.
Fidelholtz, J; Lefkowitz, M; Rawls, J; Rüegg, P; Shi, Y; Smith, W; Zack, A, 2002
)
"In this study, tegaserod at doses of 4 and 12 mg/day was safe and not associated with complications of diarrhea or serious adverse events."( Safety and tolerability of tegaserod in patients with irritable bowel syndrome and diarrhea symptoms.
Fidelholtz, J; Lefkowitz, M; Rawls, J; Rüegg, P; Shi, Y; Smith, W; Zack, A, 2002
)
" The most common adverse events, classified as related to tegaserod for any dose, were mild and transient diarrhoea (10."( Long-term safety of tegaserod in patients with constipation-predominant irritable bowel syndrome.
Earnest, DL; Langaker, KE; Nault, B; Otten, MH; Pecher, E; Pruitt, RE; Rojavin, MA; Snape, WJ; Tougas, G, 2002
)
" The adverse event profile, clinical laboratory evaluations, vital signs and electrocardiogram recordings revealed no evidence of any unexpected adverse events, and suggest that treatment is safe over a 12-month period."( Long-term safety of tegaserod in patients with constipation-predominant irritable bowel syndrome.
Earnest, DL; Langaker, KE; Nault, B; Otten, MH; Pecher, E; Pruitt, RE; Rojavin, MA; Snape, WJ; Tougas, G, 2002
)
" Headache was the most commonly reported adverse event (12."( An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome.
Bak, YT; Chang, FY; Gwee, KA; Jones, J; Kellow, J; Lee, OY; Mazlam, MZ; Thongsawat, S; Wagner, A; Yuen, H, 2003
)
" Safety was assessed by adverse events, laboratory evaluations, blood pressure and heart rates, Physical examination and ECG evaluations."( [A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of tegaserod in Chinese patients with constipation-predominant irritable bowel syndrome].
, 2003
)
" Regarding adverse events during the treatment period, about 10% of the patients in the tegaserod group experienced an adverse event compared to 6% in the placebo group."( [A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of tegaserod in Chinese patients with constipation-predominant irritable bowel syndrome].
, 2003
)
"To discuss the need for safe and effective therapy for patients with irritable bowel syndrome (IBS) and to provide up-to-date information on the safety and tolerability profile of tegaserod, a novel treatment for women with IBS whose primary bowel symptom is constipation."( Safety and tolerability of tegaserod in irritable bowel syndrome management.
Berardi, RR,
)
" Traditional agents, although occasionally effective, often cause adverse effects."( Safety and tolerability of tegaserod in irritable bowel syndrome management.
Berardi, RR,
)
"Tegaserod is effective in treating multiple IBS symptoms in women with IBS whose primary bowel symptom is constipation, and it is safe and well tolerated."( Safety and tolerability of tegaserod in irritable bowel syndrome management.
Berardi, RR,
)
" Headache was the most commonly reported adverse event (8."( A double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndrome.
Bang, C; Elsborg, L; Holme, I; Jones, J; Nyhlin, H; Rüegg, P; Silvennoinen, J; Wagner, A, 2004
)
" is an effective, safe and well-tolerated treatment in patients suffering from IBS without diarrhoea as primary bowel symptom."( A double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndrome.
Bang, C; Elsborg, L; Holme, I; Jones, J; Nyhlin, H; Rüegg, P; Silvennoinen, J; Wagner, A, 2004
)
" Gastrointestinal symptoms are the most common adverse effects of tegaserod therapy."( Safety profile of tegaserod, a 5-HT4 receptor agonist, for the treatment of irritable bowel syndrome.
Hasler, WL; Schoenfeld, P, 2004
)
" Other extra-gastrointestinal adverse events occurred with similar frequency in tegaserod-treated and placebo-treated patients."( Review article: the safety profile of tegaserod.
Schoenfeld, P, 2004
)
" Adverse events (AEs) and serious AEs were recorded, along with detailed assessment of diarrhoeal episodes."( Tegaserod is safe, well tolerated and effective in the treatment of patients with non-diarrhoea irritable bowel syndrome.
Beglinger, C; Bobalj, NG; Coello, N; Fried, M; Michetti, P; Minor, N, 2005
)
" Safety and tolerability were assessed by monitoring adverse events (AEs), laboratory parameters, vital signs, and electrocardiograms."( Safety, tolerability, and efficacy of tegaserod over 13 months in patients with chronic constipation.
Dunger-Baldauf, C; Earnest, DL; Kamm, MA; Müller-Lissner, S; Musoglu, A; Shetzline, MA, 2006
)
" Safety was also assessed, based on the incidence and severity of adverse events (AEs)."( A randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of tegaserod in patients from China with chronic constipation.
diTommaso, S; Huang, J; Ke, MY; Lin, SR; Luo, JY; Walter, V; Wang, JY; Yuan, YZ, 2007
)
" Safety and tolerability were assessed by recording adverse events (AE)."( Safety, tolerability and satisfaction with tegaserod therapy in Asia-Pacific patients with irritable bowel syndrome with constipation.
Fock, KM; Wagner, A, 2007
)
" Our aim was to review patients in our practice prescribed tegaserod to determine if any of them had suffered a cardiovascular event or other significant adverse effects while on this therapy."( Safety and efficacy of tegaserod therapy in patients with irritable bowel syndrome or chronic constipation.
Al-Judaibi, B; Chande, N; Gregor, J, 2010
)
" These patients were contacted and questioned about symptoms of cardiovascular events or other adverse events while on tegaserod."( Safety and efficacy of tegaserod therapy in patients with irritable bowel syndrome or chronic constipation.
Al-Judaibi, B; Chande, N; Gregor, J, 2010
)
"5%) experience no adverse events and 14 patients (27."( Safety and efficacy of tegaserod therapy in patients with irritable bowel syndrome or chronic constipation.
Al-Judaibi, B; Chande, N; Gregor, J, 2010
)
"The present review has several objectives, the first of which is to review the pharmacology and selectivity of serotonergic agents to contrast the older serotonergic agents (which were withdrawn because of cardiac or vascular adverse effects) with the newer generation serotonin receptor subtype 4 agonists."( New treatment options for chronic constipation: mechanisms, efficacy and safety.
Camilleri, M, 2011
)
"The nonselective 5-HT(4) receptor agonists, cisapride and tegaserod have been associated with cardiovascular adverse events (AEs)."( Systematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disorders.
Camilleri, M; Chang, L; Chey, WD; De Maeyer, JH; Galligan, JJ; Lacy, BE; Müller-Lissner, S; Quigley, EM; Schuurkes, J; Stanghellini, V; Tack, J, 2012
)
"The Federal Adverse Event Reporting System was queried for the time between January 2004 and September 2015."( Ischemic Colitis as a Complication of Medication Use: An Analysis of the Federal Adverse Event Reporting System.
Bielefeldt, K, 2016
)
" In 8 %, the adverse event contributed to the patient's death with male sex and older age predicting fatal outcomes."( Ischemic Colitis as a Complication of Medication Use: An Analysis of the Federal Adverse Event Reporting System.
Bielefeldt, K, 2016
)
" This information may not only explain the development of this serious adverse event, but could also guide treatment decisions, cautioning healthcare providers when considering these agents in persons with known risk factors or other drugs that may increase their risk of IC."( Ischemic Colitis as a Complication of Medication Use: An Analysis of the Federal Adverse Event Reporting System.
Bielefeldt, K, 2016
)
" Although the majority of serotonin receptor ligands relieve global symptoms, there are also some adverse effects, which can be dangerous for patients."( Efficacy and Safety of Serotonin Receptor Ligands in the Treatment of Irritable Bowel Syndrome: A Review.
Binienda, A; Fichna, J; Salaga, M; Storr, M, 2018
)
" Women <65 years of age without a history of cardiovascular ischemic events and ≤1 cardiovascular risk factor receiving tegaserod experienced no major adverse cardiovascular event(s)."( Re-evaluation of the Cardiovascular Safety Profile of Tegaserod: A Review of the Clinical Data.
Brenner, DM; Chey, WD; Lacy, BE, 2022
)
"Two independent, external adjudications suggest that tegaserod is safe for women <65 years of age with irritable bowel syndrome with constipation, no history of cardiovascular ischemic events, and ≤1 cardiovascular risk factor."( Re-evaluation of the Cardiovascular Safety Profile of Tegaserod: A Review of the Clinical Data.
Brenner, DM; Chey, WD; Lacy, BE, 2022
)

Pharmacokinetics

Tegaserod has been shown to have prokinetic effects in horses, but pharmacokinetic information is not currently available. Tegaserod at dosages of 1 to 12 mg/day exerts pharmacodynamic actions in the upper and the lower gastrointestinal tract.

ExcerptReference
" Basic pharmacokinetic characteristics of HTF were derived."( First pharmacokinetic-pharmacodynamic study in humans with a selective 5-hydroxytryptamine4 receptor agonist.
Appel, S; Duvauchelle, T; Hubert, M; Kumle, A, 1997
)
"To explore the pharmacodynamic effects of the new promotile agent SDZ HTF 919, a selective partial 5-HT4 receptor agonist, in healthy subjects."( Clinical pharmacodynamics of SDZ HTF 919, a new 5-HT4 receptor agonist, in a model of slow colonic transit.
Appel, S; Kumle, A; Meier, R, 1997
)
"A pharmacodynamic model was applied to prolong colonic transit by dietary means."( Clinical pharmacodynamics of SDZ HTF 919, a new 5-HT4 receptor agonist, in a model of slow colonic transit.
Appel, S; Kumle, A; Meier, R, 1997
)
" Pharmacokinetic parameters were obtained by noncompartmental methods."( Integrated modelling of the clinical pharmacokinetics of SDZ HTF 919, a novel selective 5-HT4 receptor agonist, following oral and intravenous administration.
Appel-Dingemanse, S; Hubert, M; Kumle, A; Legangneux, E; Lemarechal, MO, 1999
)
"This study assessed the pharmacokinetic profiles of administering tegaserod (HTF 919) at different time intervals with respect to a meal."( Effect of meal timing not critical for the pharmacokinetics of tegaserod (HTF 919).
Alladina, L; Guerret, M; Khalilieh, S; Lau, H; Laurent, AL; McLeod, JF; Osborne, S; Zhou, H, 1999
)
" There was no effect of age or gender on tmax and Cmax."( The pharmacokinetics of the novel promotile drug, tegaserod, are similar in healthy subjects-male and female, elderly and young.
Appel-Dingemanse, S; Campestrini, J; Horowitz, A; McLeod, J; Osborne, S, 2001
)
" This study was designed to assess the effect of tegaserod on the single-dose pharmacokinetic and safety profile of theophylline."( Tegaserod coadministration does not alter the pharmacokinetics of theophylline in healthy subjects.
Appel-Dingemanse, S; Khalilieh, S; Lasseter, K; McLeod, JF; Osborne, S; Pommier, F; Svendsen, K; Zhou, H, 2001
)
" Tegaserod at dosages of 1 to 12 mg/day exerts pharmacodynamic actions in the upper and the lower gastrointestinal tract, accelerating small bowel and colonic transit in patients with IBS."( Clinical pharmacokinetics of tegaserod, a serotonin 5-HT(4) receptor partial agonist with promotile activity.
Appel-Dingemanse, S, 2002
)
"Tegaserod, a serotonin agonist, has been shown to have prokinetic effects in horses, but pharmacokinetic information is not currently available."( Pharmacokinetics and in vitro effects of tegaserod, a serotonin 5-hydroxytryptamine 4 (5-HT4) receptor agonist with prokinetic activity in horses.
Craigmill, AL; Delco, ML; Nieto, JE; Snyder, JR; Stanley, SD, 2007
)
"3) l/h, respectively; time to Cmax (Tmax) were (1."( Determination of tegaserod by LC-ESI-MS/MS and its application to a pharmacokinetic study in healthy Chinese volunteers.
Bian, XJ; Ding, L; Fan, HW; Xiao, DW; Zhu, YB; Zou, JJ, 2008
)
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)

Bioavailability

ExcerptReference
" Based on the absorption analyses, we found that the reduction in the bioavailability of tegaserod under fed conditions was primarily due to a decrease in the extent of absorption and less so to a decrease in the absorption rate(s)."( Effect of meal timing not critical for the pharmacokinetics of tegaserod (HTF 919).
Alladina, L; Guerret, M; Khalilieh, S; Lau, H; Laurent, AL; McLeod, JF; Osborne, S; Zhou, H, 1999
)
" Absolute bioavailability is about 10% under fasted conditions."( Clinical pharmacokinetics of tegaserod, a serotonin 5-HT(4) receptor partial agonist with promotile activity.
Appel-Dingemanse, S, 2002
)
" The optimum formulation was evaluated for in vitro release rate and in vivo bioavailability study on beagle dogs."( In vitro and in vivo evaluation of tegaserod maleate pH-dependent tablets.
Chen, GH; Deng, WB; Li, SM; Repka, MA; Thumma, S; Zhang, SQ, 2008
)
"Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)."( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010
)
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)

Dosage Studied

TD-5108 was approximately twofold less potent than tegaserod following intravenous dosing. It was 6- or 86-fold more potent than cisapride or mosapride, respectively, after intraduodenal administration.

ExcerptReference
" The lack of effect at lower and higher SDZ HTF 919 doses suggests a biphasic dose-response relationship for total colonic transit time."( Clinical pharmacodynamics of SDZ HTF 919, a new 5-HT4 receptor agonist, in a model of slow colonic transit.
Appel, S; Kumle, A; Meier, R, 1997
)
" This increase in exposure is judged not to be clinically relevant because it is within the variability in the pharmacokinetics parameters of tegaserod and because the dose-response relationship of tegaserod is relatively shallow."( The pharmacokinetics of the novel promotile drug, tegaserod, are similar in healthy subjects-male and female, elderly and young.
Appel-Dingemanse, S; Campestrini, J; Horowitz, A; McLeod, J; Osborne, S, 2001
)
" Likewise, the predicted arithmetic mean steady-state peak concentration (C(SS,min)) and AUC at steady state during a dosing interval (AUC(SS,tau)) have a similar decrease."( The effects of tegaserod (HTF 919) on the pharmacokinetics and pharmacodynamics of digoxin in healthy subjects.
Appel-Dingemanse, S; Horowitz, A; Hubert, M; Ledford, PC; McLeod, JF; Osborne, S; Zhou, H, 2001
)
" No dosage adjustment is required in elderly patients or those with mild to moderate hepatic or renal impairment."( Clinical pharmacokinetics of tegaserod, a serotonin 5-HT(4) receptor partial agonist with promotile activity.
Appel-Dingemanse, S, 2002
)
" The recommended dosage for patients aged >18 years with constipation-predominant IBS is 6 mg PO BID before meals for 4 to 6 weeks, with an additional 4 to 6 weeks of treatment if initial therapy is partially effective."( Tegaserod maleate in the treatment of irritable bowel syndrome: a clinical review.
Rivkin, A, 2003
)
"3 or 1 mg kg(-1)) inhibited contractions of the stomach fundus in anaesthetized rats in response to intravenous dosing of alpha-methyl 5-HT (0."( The 5-HT4 receptor agonist, tegaserod, is a potent 5-HT2B receptor antagonist in vitro and in vivo.
Armstrong, SR; Beattie, DT; Humphrey, PP; Mai, N; Marquess, D; McCullough, JL; Pulido-Rios, T; Richardson, C; Sandlund, C; Smith, JA; Vickery, RG, 2004
)
" Spheres were given via stomach tube prior to the first dosing of tegaserod or vehicle."( Tegaserod (HTF 919) stimulates gut motility in normal horses.
Hildebrand, J; Lippold, BS; Straub, R, 2004
)
" Bolus transit time was similar during dosing with placebo (7."( Effects of a 5-HT(4) receptor agonist on oesophageal function and gastro-oesophageal reflux: studies using combined impedance-manometry and combined impedance-pH.
Agrawal, A; Allan, R; Castell, DO; Freeman, J; Gale, J; Hargreaves, K; Mainie, I; Tutuian, R, 2006
)
" Regarding adverse effect, mild diarrhea was found in 2 cases and was relieved when the dosage was decreased."( [Effect of combined drug treatment on megacolon with severe constipation].
Ding, ZL; Ke, MY; Sun, XH; Wang, ZF, 2007
)
" On a molar basis, TD-5108 was approximately twofold less potent than tegaserod following intravenous dosing but 6- or 86-fold more potent than cisapride or mosapride, respectively, and 9- or 18-fold more potent than tegaserod or cisapride, respectively, after intraduodenal administration."( The in vivo gastrointestinal activity of TD-5108, a selective 5-HT(4) receptor agonist with high intrinsic activity.
Armstrong, SR; Beattie, DT; Humphrey, PP; Marquess, D; Sandlund, C; Shaw, JP; Smith, JA; Taylor, JA, 2008
)
" The formulation's goal was to allow the dosage form to pass through the stomach intact, start disintegrating in the upper small intestine and slowly release the active in a controlled manner."( Development and evaluation of a pH-dependent sustained release tablet for irritable bowel syndrome.
Chen, GH; Li, SM; Rahman, Z; Repka, MA; Thumma, S; Zhang, SQ, 2009
)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
serotonergic agonistAn agent that has an affinity for serotonin receptors and is able to mimic the effects of serotonin by stimulating the physiologic activity at the cell receptors. Serotonin agonists are used as antidepressants, anxiolytics, and in the treatment of migraine disorders.
gastrointestinal drugA drug used for its effects on the gastrointestinal system, e.g. controlling gastric acidity, regulating gastrointestinal motility and water flow, and improving digestion.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
guanidinesAny organonitrogen compound containing a carbamimidamido (guanidino) group. Guanidines have the general structure (R(1)R(2)N)(R(3)R(4)N)C=N-R(5) and are related structurally to amidines and ureas.
carboxamidineCompounds having the structure RC(=NR)NR2. The term is used as a suffix in systematic nomenclature to denote the -C(=NH)NH2 group including its carbon atom.
hydrazinesHydrazine (diazane) and its substituted derivatives.
indolesAny compound containing an indole skeleton.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (47)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
acetylcholinesteraseHomo sapiens (human)Potency38.90180.002541.796015,848.9004AID1347398
hypoxia-inducible factor 1 alpha subunitHomo sapiens (human)Potency26.83253.189029.884159.4836AID1224846; AID1224894
RAR-related orphan receptor gammaMus musculus (house mouse)Potency32.25430.006038.004119,952.5996AID1159521; AID1159523
SMAD family member 2Homo sapiens (human)Potency27.92380.173734.304761.8120AID1346859; AID1346924; AID1347035
Fumarate hydrataseHomo sapiens (human)Potency35.48130.00308.794948.0869AID1347053
PPM1D proteinHomo sapiens (human)Potency6.58420.00529.466132.9993AID1347411
SMAD family member 3Homo sapiens (human)Potency27.92380.173734.304761.8120AID1346859; AID1346924; AID1347035
TDP1 proteinHomo sapiens (human)Potency29.85540.000811.382244.6684AID686979
GLI family zinc finger 3Homo sapiens (human)Potency1.93720.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency10.01500.000221.22318,912.5098AID1259243; AID1259247
caspase 7, apoptosis-related cysteine proteaseHomo sapiens (human)Potency11.88320.013326.981070.7614AID1346978
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency32.93890.000657.913322,387.1992AID1259377; AID1259378; AID1259394
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency16.60010.001022.650876.6163AID1224838; AID1224839; AID1224893
progesterone receptorHomo sapiens (human)Potency23.31740.000417.946075.1148AID1346784; AID1346795
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency34.67130.01237.983543.2770AID1645841
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency21.71360.003041.611522,387.1992AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency11.46860.000817.505159.3239AID1159527; AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency20.02830.001530.607315,848.9004AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
farnesoid X nuclear receptorHomo sapiens (human)Potency33.48890.375827.485161.6524AID743217; AID743220; AID743239
pregnane X nuclear receptorHomo sapiens (human)Potency21.22610.005428.02631,258.9301AID1346982; AID1346985
estrogen nuclear receptor alphaHomo sapiens (human)Potency27.12360.000229.305416,493.5996AID1259244; AID1259248
cytochrome P450 2D6Homo sapiens (human)Potency0.21880.00108.379861.1304AID1645840
polyproteinZika virusPotency35.48130.00308.794948.0869AID1347053
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency32.27490.001024.504861.6448AID743212; AID743215; AID743227
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency33.48890.001019.414170.9645AID743191
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency13.44810.023723.228263.5986AID743223
caspase-3Homo sapiens (human)Potency11.88320.013326.981070.7614AID1346978
thyroid stimulating hormone receptorHomo sapiens (human)Potency29.84930.001628.015177.1139AID1259385; AID1259395
activating transcription factor 6Homo sapiens (human)Potency26.83250.143427.612159.8106AID1159516; AID1159519
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency27.357419.739145.978464.9432AID1159509; AID1159518
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency21.45520.057821.109761.2679AID1159526; AID1159528
Histone H2A.xCricetulus griseus (Chinese hamster)Potency55.56270.039147.5451146.8240AID1224845; AID1224896
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency15.84890.01789.637444.6684AID588834
heat shock protein beta-1Homo sapiens (human)Potency31.66790.042027.378961.6448AID743210; AID743228
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency18.83220.000627.21521,122.0200AID743202
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency18.10560.005612.367736.1254AID624032
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency26.60320.001557.789015,848.9004AID1259244
Interferon betaHomo sapiens (human)Potency10.18990.00339.158239.8107AID1347407; AID1347411
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency26.60320.001551.739315,848.9004AID1259244
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
5-hydroxytryptamine receptor 4Cavia porcellus (domestic guinea pig)Ki10.00000.00000.887110.0000AID416399
5-hydroxytryptamine receptor 1DHomo sapiens (human)Ki0.10000.00010.808710.0000AID758760
5-hydroxytryptamine receptor 2AHomo sapiens (human)Ki0.10000.00000.385510.0000AID758758
5-hydroxytryptamine receptor 2CHomo sapiens (human)Ki0.10000.00010.954910.0000AID758759
5-hydroxytryptamine receptor 7Homo sapiens (human)Ki0.10000.00030.380610.0000AID758756
5-hydroxytryptamine receptor 2BHomo sapiens (human)Ki0.00200.00030.769310.0000AID758757
5-hydroxytryptamine receptor 3AHomo sapiens (human)Ki6.25590.00000.74119.9000AID416399; AID758781
5-hydroxytryptamine receptor 4Homo sapiens (human)Ki0.00940.00000.443910.0000AID378830; AID416400; AID672173; AID684471; AID758785
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
5-hydroxytryptamine receptor 4Cavia porcellus (domestic guinea pig)EC50 (µMol)0.00950.00200.47533.2000AID683465; AID758752
5-hydroxytryptamine receptor 4Homo sapiens (human)EC50 (µMol)0.00480.00060.08791.1220AID672175; AID672319; AID672321; AID684473; AID758784
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (117)

Processvia Protein(s)Taxonomy
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 1DHomo sapiens (human)
intestine smooth muscle contraction5-hydroxytryptamine receptor 1DHomo sapiens (human)
regulation of locomotion5-hydroxytryptamine receptor 1DHomo sapiens (human)
vasoconstriction5-hydroxytryptamine receptor 1DHomo sapiens (human)
regulation of behavior5-hydroxytryptamine receptor 1DHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 1DHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 1DHomo sapiens (human)
adenylate cyclase-inhibiting serotonin receptor signaling pathway5-hydroxytryptamine receptor 1DHomo sapiens (human)
temperature homeostasis5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of cytokine production involved in immune response5-hydroxytryptamine receptor 2AHomo sapiens (human)
glycolytic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
intracellular calcium ion homeostasis5-hydroxytryptamine receptor 2AHomo sapiens (human)
activation of phospholipase C activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of cytosolic calcium ion concentration5-hydroxytryptamine receptor 2AHomo sapiens (human)
memory5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of cell population proliferation5-hydroxytryptamine receptor 2AHomo sapiens (human)
response to xenobiotic stimulus5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
regulation of dopamine secretion5-hydroxytryptamine receptor 2AHomo sapiens (human)
artery smooth muscle contraction5-hydroxytryptamine receptor 2AHomo sapiens (human)
urinary bladder smooth muscle contraction5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of heat generation5-hydroxytryptamine receptor 2AHomo sapiens (human)
negative regulation of potassium ion transport5-hydroxytryptamine receptor 2AHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of neuron apoptotic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein localization to cytoskeleton5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of fat cell differentiation5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of glycolytic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of vasoconstriction5-hydroxytryptamine receptor 2AHomo sapiens (human)
symbiont entry into host cell5-hydroxytryptamine receptor 2AHomo sapiens (human)
sensitization5-hydroxytryptamine receptor 2AHomo sapiens (human)
behavioral response to cocaine5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of inflammatory response5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylation5-hydroxytryptamine receptor 2AHomo sapiens (human)
detection of temperature stimulus involved in sensory perception of pain5-hydroxytryptamine receptor 2AHomo sapiens (human)
detection of mechanical stimulus involved in sensory perception of pain5-hydroxytryptamine receptor 2AHomo sapiens (human)
release of sequestered calcium ion into cytosol5-hydroxytryptamine receptor 2AHomo sapiens (human)
negative regulation of synaptic transmission, glutamatergic5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 2AHomo sapiens (human)
presynaptic modulation of chemical synaptic transmission5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of execution phase of apoptosis5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of platelet aggregation5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of DNA biosynthetic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 2AHomo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway5-hydroxytryptamine receptor 2AHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 2AHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 2AHomo sapiens (human)
behavioral fear response5-hydroxytryptamine receptor 2CHomo sapiens (human)
intracellular calcium ion homeostasis5-hydroxytryptamine receptor 2CHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
locomotory behavior5-hydroxytryptamine receptor 2CHomo sapiens (human)
feeding behavior5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process5-hydroxytryptamine receptor 2CHomo sapiens (human)
cGMP-mediated signaling5-hydroxytryptamine receptor 2CHomo sapiens (human)
regulation of nervous system process5-hydroxytryptamine receptor 2CHomo sapiens (human)
regulation of appetite5-hydroxytryptamine receptor 2CHomo sapiens (human)
regulation of corticotropin-releasing hormone secretion5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of fat cell differentiation5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of calcium-mediated signaling5-hydroxytryptamine receptor 2CHomo sapiens (human)
release of sequestered calcium ion into cytosol5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 2CHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 2CHomo sapiens (human)
smooth muscle contraction5-hydroxytryptamine receptor 7Homo sapiens (human)
circadian rhythm5-hydroxytryptamine receptor 7Homo sapiens (human)
blood circulation5-hydroxytryptamine receptor 7Homo sapiens (human)
vasoconstriction5-hydroxytryptamine receptor 7Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 7Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 7Homo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 7Homo sapiens (human)
neural crest cell migration5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of cytokine production5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of endothelial cell proliferation5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled receptor internalization5-hydroxytryptamine receptor 2BHomo sapiens (human)
heart morphogenesis5-hydroxytryptamine receptor 2BHomo sapiens (human)
cardiac muscle hypertrophy5-hydroxytryptamine receptor 2BHomo sapiens (human)
intracellular calcium ion homeostasis5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
activation of phospholipase C activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of cell population proliferation5-hydroxytryptamine receptor 2BHomo sapiens (human)
response to xenobiotic stimulus5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process5-hydroxytryptamine receptor 2BHomo sapiens (human)
neural crest cell differentiation5-hydroxytryptamine receptor 2BHomo sapiens (human)
intestine smooth muscle contraction5-hydroxytryptamine receptor 2BHomo sapiens (human)
phosphorylation5-hydroxytryptamine receptor 2BHomo sapiens (human)
calcium-mediated signaling5-hydroxytryptamine receptor 2BHomo sapiens (human)
cGMP-mediated signaling5-hydroxytryptamine receptor 2BHomo sapiens (human)
vasoconstriction5-hydroxytryptamine receptor 2BHomo sapiens (human)
negative regulation of apoptotic process5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of canonical NF-kappaB signal transduction5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of MAP kinase activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction5-hydroxytryptamine receptor 2BHomo sapiens (human)
embryonic morphogenesis5-hydroxytryptamine receptor 2BHomo sapiens (human)
regulation of behavior5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of nitric-oxide synthase activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
release of sequestered calcium ion into cytosol5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of cell division5-hydroxytryptamine receptor 2BHomo sapiens (human)
ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2BHomo sapiens (human)
protein kinase C signaling5-hydroxytryptamine receptor 2BHomo sapiens (human)
cellular response to temperature stimulus5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 2BHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 2BHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 3AHomo sapiens (human)
monoatomic ion transmembrane transport5-hydroxytryptamine receptor 3AHomo sapiens (human)
excitatory postsynaptic potential5-hydroxytryptamine receptor 3AHomo sapiens (human)
inorganic cation transmembrane transport5-hydroxytryptamine receptor 3AHomo sapiens (human)
regulation of presynaptic membrane potential5-hydroxytryptamine receptor 3AHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 3AHomo sapiens (human)
regulation of membrane potential5-hydroxytryptamine receptor 3AHomo sapiens (human)
G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 4Homo sapiens (human)
maintenance of gastrointestinal epithelium5-hydroxytryptamine receptor 4Homo sapiens (human)
regulation of appetite5-hydroxytryptamine receptor 4Homo sapiens (human)
mucus secretion5-hydroxytryptamine receptor 4Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 4Homo sapiens (human)
large intestinal transit5-hydroxytryptamine receptor 4Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 4Homo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 4Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (21)

Processvia Protein(s)Taxonomy
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 1DHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 1DHomo sapiens (human)
Gq/11-coupled serotonin receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
virus receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein tyrosine kinase activator activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
identical protein binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein-containing complex binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
Gq/11-coupled serotonin receptor activity5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 2CHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
identical protein binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 2CHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 7Homo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 7Homo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 7Homo sapiens (human)
Gq/11-coupled serotonin receptor activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
G-protein alpha-subunit binding5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
GTPase activator activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 2BHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 2BHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 3AHomo sapiens (human)
serotonin-gated monoatomic cation channel activity5-hydroxytryptamine receptor 3AHomo sapiens (human)
identical protein binding5-hydroxytryptamine receptor 3AHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 3AHomo sapiens (human)
ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potential5-hydroxytryptamine receptor 3AHomo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potential5-hydroxytryptamine receptor 3AHomo sapiens (human)
excitatory extracellular ligand-gated monoatomic ion channel activity5-hydroxytryptamine receptor 3AHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 4Homo sapiens (human)
protein binding5-hydroxytryptamine receptor 4Homo sapiens (human)
serotonin receptor activity5-hydroxytryptamine receptor 4Homo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (25)

Processvia Protein(s)Taxonomy
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
plasma membrane5-hydroxytryptamine receptor 1DHomo sapiens (human)
synapse5-hydroxytryptamine receptor 1DHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 1DHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 1DHomo sapiens (human)
neurofilament5-hydroxytryptamine receptor 2AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
caveola5-hydroxytryptamine receptor 2AHomo sapiens (human)
axon5-hydroxytryptamine receptor 2AHomo sapiens (human)
cytoplasmic vesicle5-hydroxytryptamine receptor 2AHomo sapiens (human)
presynaptic membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
neuronal cell body5-hydroxytryptamine receptor 2AHomo sapiens (human)
dendritic shaft5-hydroxytryptamine receptor 2AHomo sapiens (human)
postsynaptic membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
cell body fiber5-hydroxytryptamine receptor 2AHomo sapiens (human)
glutamatergic synapse5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 2AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 2AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2CHomo sapiens (human)
synapse5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 2CHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2CHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 2CHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 7Homo sapiens (human)
trans-Golgi network membrane5-hydroxytryptamine receptor 7Homo sapiens (human)
synapse5-hydroxytryptamine receptor 7Homo sapiens (human)
dendrite5-hydroxytryptamine receptor 7Homo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 7Homo sapiens (human)
nucleoplasm5-hydroxytryptamine receptor 2BHomo sapiens (human)
cytoplasm5-hydroxytryptamine receptor 2BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2BHomo sapiens (human)
synapse5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 2BHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 2BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 3AHomo sapiens (human)
cleavage furrow5-hydroxytryptamine receptor 3AHomo sapiens (human)
postsynaptic membrane5-hydroxytryptamine receptor 3AHomo sapiens (human)
serotonin-activated cation-selective channel complex5-hydroxytryptamine receptor 3AHomo sapiens (human)
synapse5-hydroxytryptamine receptor 3AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 3AHomo sapiens (human)
transmembrane transporter complex5-hydroxytryptamine receptor 3AHomo sapiens (human)
neuron projection5-hydroxytryptamine receptor 3AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 4Homo sapiens (human)
cytoplasm5-hydroxytryptamine receptor 4Homo sapiens (human)
endosome5-hydroxytryptamine receptor 4Homo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 4Homo sapiens (human)
membrane5-hydroxytryptamine receptor 4Homo sapiens (human)
synapse5-hydroxytryptamine receptor 4Homo sapiens (human)
dendrite5-hydroxytryptamine receptor 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (134)

Assay IDTitleYearJournalArticle
AID444050Fraction unbound in human plasma2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID672177Inhibition of human ERG expressed in CHO cells at 3 uM2012Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14
Discovery, oral pharmacokinetics and in vivo efficacy of a highly selective 5-HT4 receptor agonist: clinical compound TD-2749.
AID758783Agonist activity at human recombinant 5HT4 receptor assessed as cAMP accumulation relative to 5-HT2013Bioorganic & medicinal chemistry letters, Jul-15, Volume: 23, Issue:14
Discovery of TD-8954, a clinical stage 5-HT(4) receptor agonist with gastrointestinal prokinetic properties.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID758752Induction of 5-HT4 receptor-mediated contraction in guinea pig longitudinal muscle myenteric plexus2013Bioorganic & medicinal chemistry letters, Jul-15, Volume: 23, Issue:14
Discovery of TD-8954, a clinical stage 5-HT(4) receptor agonist with gastrointestinal prokinetic properties.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID416399Binding affinity at 5HT3 receptor2009Bioorganic & medicinal chemistry, Mar-15, Volume: 17, Issue:6
Novel antagonists of serotonin-4 receptors: synthesis and biological evaluation of pyrrolothienopyrazines.
AID444055Fraction absorbed in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID758757Binding affinity to serotonin 5-HT2B receptor (unknown origin)2013Bioorganic & medicinal chemistry letters, Jul-15, Volume: 23, Issue:14
Discovery of TD-8954, a clinical stage 5-HT(4) receptor agonist with gastrointestinal prokinetic properties.
AID758780Inhibition of human ERG channel at 3 uM2013Bioorganic & medicinal chemistry letters, Jul-15, Volume: 23, Issue:14
Discovery of TD-8954, a clinical stage 5-HT(4) receptor agonist with gastrointestinal prokinetic properties.
AID6723255-HT4 receptor-mediated esophageal relaxation in anesthetized rat (following i.v. administration) using digital sonomicrometry2012Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14
Discovery, oral pharmacokinetics and in vivo efficacy of a highly selective 5-HT4 receptor agonist: clinical compound TD-2749.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID758748Intrinsic activity at 5-HT4 receptor-mediated contraction in guinea pig longitudinal muscle myenteric plexus2013Bioorganic & medicinal chemistry letters, Jul-15, Volume: 23, Issue:14
Discovery of TD-8954, a clinical stage 5-HT(4) receptor agonist with gastrointestinal prokinetic properties.
AID431674Cmax in Sprague-Dawley rat at 5 mg/kg, po2009Journal of medicinal chemistry, Sep-10, Volume: 52, Issue:17
A multivalent approach to the design and discovery of orally efficacious 5-HT4 receptor agonists.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID758784Agonist activity at human recombinant 5HT4 receptor assessed as cAMP accumulation2013Bioorganic & medicinal chemistry letters, Jul-15, Volume: 23, Issue:14
Discovery of TD-8954, a clinical stage 5-HT(4) receptor agonist with gastrointestinal prokinetic properties.
AID684471Displacement of [3H]GR113808 from human recombinant 5HT4c receptor expressed in HEK293 cells2012Bioorganic & medicinal chemistry letters, Oct-01, Volume: 22, Issue:19
Discovery, oral pharmacokinetics and in vivo efficacy of velusetrag, a highly selective 5-HT(4) receptor agonist that has achieved proof-of-concept in patients with chronic idiopathic constipation.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID234717Relative efficacy compared to serotonin(1) in 5-hydroxytryptamine 4 assay1995Journal of medicinal chemistry, Jun-23, Volume: 38, Issue:13
The serotonin 5-HT4 receptor. 2. Structure-activity studies of the indole carbazimidamide class of agonists.
AID444056Fraction escaping gut-wall elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID416400Binding affinity at 5HT4 receptor2009Bioorganic & medicinal chemistry, Mar-15, Volume: 17, Issue:6
Novel antagonists of serotonin-4 receptors: synthesis and biological evaluation of pyrrolothienopyrazines.
AID672323Agonist activity at 5HT4 receptor in guinea pig colon assessed as longitudinal muscle plexus contraction2012Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14
Discovery, oral pharmacokinetics and in vivo efficacy of a highly selective 5-HT4 receptor agonist: clinical compound TD-2749.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID439334Agonist activity at human NPFF1 receptor expressed in cells assessed as beta-galactosidase levels at 10 mM after 5 days2009Journal of medicinal chemistry, Nov-12, Volume: 52, Issue:21
Discovery of selective nonpeptidergic neuropeptide FF2 receptor agonists.
AID758781Binding affinity to human recombinant 5HT3 receptor2013Bioorganic & medicinal chemistry letters, Jul-15, Volume: 23, Issue:14
Discovery of TD-8954, a clinical stage 5-HT(4) receptor agonist with gastrointestinal prokinetic properties.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID444053Renal clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID672173Displacement of [3H]GR113808 from human recombinant 5HT4C receptor expressed in HEK293 cells2012Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14
Discovery, oral pharmacokinetics and in vivo efficacy of a highly selective 5-HT4 receptor agonist: clinical compound TD-2749.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID444051Total clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID758738Agonist activity at 5HT4 receptor in ID dosed rat assessed as dose required to cause esophageal relaxation of 0.1 mm2013Bioorganic & medicinal chemistry letters, Jul-15, Volume: 23, Issue:14
Discovery of TD-8954, a clinical stage 5-HT(4) receptor agonist with gastrointestinal prokinetic properties.
AID684476Half life in rat liver microsomes2012Bioorganic & medicinal chemistry letters, Oct-01, Volume: 22, Issue:19
Discovery, oral pharmacokinetics and in vivo efficacy of velusetrag, a highly selective 5-HT(4) receptor agonist that has achieved proof-of-concept in patients with chronic idiopathic constipation.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID758760Binding affinity to serotonin 5-HT1D receptor (unknown origin)2013Bioorganic & medicinal chemistry letters, Jul-15, Volume: 23, Issue:14
Discovery of TD-8954, a clinical stage 5-HT(4) receptor agonist with gastrointestinal prokinetic properties.
AID683467Induction of 5HT4-receptor mediated esophagal relaxation in iv dosed Sprague-Dawley rat2012Bioorganic & medicinal chemistry letters, Oct-01, Volume: 22, Issue:19
Discovery, oral pharmacokinetics and in vivo efficacy of velusetrag, a highly selective 5-HT(4) receptor agonist that has achieved proof-of-concept in patients with chronic idiopathic constipation.
AID758779Half life in rat liver micrososmes2013Bioorganic & medicinal chemistry letters, Jul-15, Volume: 23, Issue:14
Discovery of TD-8954, a clinical stage 5-HT(4) receptor agonist with gastrointestinal prokinetic properties.
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID758785Binding affinity to human recombinant 5HT4 receptor2013Bioorganic & medicinal chemistry letters, Jul-15, Volume: 23, Issue:14
Discovery of TD-8954, a clinical stage 5-HT(4) receptor agonist with gastrointestinal prokinetic properties.
AID758759Binding affinity to serotonin 5-HT2C receptor (unknown origin)2013Bioorganic & medicinal chemistry letters, Jul-15, Volume: 23, Issue:14
Discovery of TD-8954, a clinical stage 5-HT(4) receptor agonist with gastrointestinal prokinetic properties.
AID672176Intrinsic activity at human 5HT4C receptor expressed at 100 fold physiological-level in HEK293 cells assessed as cAMP accumulation relative to 5HT2012Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14
Discovery, oral pharmacokinetics and in vivo efficacy of a highly selective 5-HT4 receptor agonist: clinical compound TD-2749.
AID672178Half life in rat liver microsomes2012Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14
Discovery, oral pharmacokinetics and in vivo efficacy of a highly selective 5-HT4 receptor agonist: clinical compound TD-2749.
AID444057Fraction escaping hepatic elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID672324Intrinsic activity at 5HT4 receptor in guinea pig colon assessed as longitudinal muscle plexus contraction relative to 5HT2012Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14
Discovery, oral pharmacokinetics and in vivo efficacy of a highly selective 5-HT4 receptor agonist: clinical compound TD-2749.
AID444058Volume of distribution at steady state in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID672179Permeability across human Caco2 cells2012Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14
Discovery, oral pharmacokinetics and in vivo efficacy of a highly selective 5-HT4 receptor agonist: clinical compound TD-2749.
AID758782Permeability across human Caco2 cells2013Bioorganic & medicinal chemistry letters, Jul-15, Volume: 23, Issue:14
Discovery of TD-8954, a clinical stage 5-HT(4) receptor agonist with gastrointestinal prokinetic properties.
AID684474Agonist activity at human recombinant 5HT4c receptor expressed in HEK293 cells at 10-fold physiological level assessed as accumulation of cAMP relative to 5HT2012Bioorganic & medicinal chemistry letters, Oct-01, Volume: 22, Issue:19
Discovery, oral pharmacokinetics and in vivo efficacy of velusetrag, a highly selective 5-HT(4) receptor agonist that has achieved proof-of-concept in patients with chronic idiopathic constipation.
AID758751Cardiotoxicity in dog coronary artery assessed as coronary artery constriction2013Bioorganic & medicinal chemistry letters, Jul-15, Volume: 23, Issue:14
Discovery of TD-8954, a clinical stage 5-HT(4) receptor agonist with gastrointestinal prokinetic properties.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID431689Induction of 5HT4 receptor-mediated relaxation of esophagus in iv dosed anesthetized Sprague-Dawley rat by digital sonomicrometry2009Journal of medicinal chemistry, Sep-10, Volume: 52, Issue:17
A multivalent approach to the design and discovery of orally efficacious 5-HT4 receptor agonists.
AID684475Inhibition of human ERG expressed in CHO cells at 3 uM2012Bioorganic & medicinal chemistry letters, Oct-01, Volume: 22, Issue:19
Discovery, oral pharmacokinetics and in vivo efficacy of velusetrag, a highly selective 5-HT(4) receptor agonist that has achieved proof-of-concept in patients with chronic idiopathic constipation.
AID439332Agonist activity at human NPFF2 receptor expressed in cells assessed as beta-galactosidase levels at 10 mM after 5 days2009Journal of medicinal chemistry, Nov-12, Volume: 52, Issue:21
Discovery of selective nonpeptidergic neuropeptide FF2 receptor agonists.
AID684477Permeability across human Caco2 cells2012Bioorganic & medicinal chemistry letters, Oct-01, Volume: 22, Issue:19
Discovery, oral pharmacokinetics and in vivo efficacy of velusetrag, a highly selective 5-HT(4) receptor agonist that has achieved proof-of-concept in patients with chronic idiopathic constipation.
AID431675Half life in Sprague-Dawley rat at 5 mg/kg, po2009Journal of medicinal chemistry, Sep-10, Volume: 52, Issue:17
A multivalent approach to the design and discovery of orally efficacious 5-HT4 receptor agonists.
AID684473Agonist activity at human recombinant 5HT4c receptor expressed in HEK293 cells at 10-fold physiological level assessed as accumulation of cAMP2012Bioorganic & medicinal chemistry letters, Oct-01, Volume: 22, Issue:19
Discovery, oral pharmacokinetics and in vivo efficacy of velusetrag, a highly selective 5-HT(4) receptor agonist that has achieved proof-of-concept in patients with chronic idiopathic constipation.
AID672175Agonist activity at human 5HT4C receptor expressed at 100 fold physiological-level in HEK293 cells assessed as cAMP accumulation2012Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14
Discovery, oral pharmacokinetics and in vivo efficacy of a highly selective 5-HT4 receptor agonist: clinical compound TD-2749.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID672319Agonist activity at human 5HT4C receptor expressed in a cell line expressing receptor at 10 fold physiological-level assessed as cAMP accumulation2012Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14
Discovery, oral pharmacokinetics and in vivo efficacy of a highly selective 5-HT4 receptor agonist: clinical compound TD-2749.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID672327Agonist activity at 5HT4 receptor in sc dosed guinea pig assessed as decrease in colonic transit time of carmine red dye after 60 mins relative to vehicle treated control2012Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14
Discovery, oral pharmacokinetics and in vivo efficacy of a highly selective 5-HT4 receptor agonist: clinical compound TD-2749.
AID1384904Reduction in acetic acid-induced acute visceral afferent neuron sensitization in Sprague-Dawley rat acute colonic hypersensitivity model assessed as decrease in visceromotor response to colorectal distension by measuring number of abdominal contractions a2018ACS medicinal chemistry letters, Jul-12, Volume: 9, Issue:7
Discovery of a First-in-Class Gut-Restricted RET Kinase Inhibitor as a Clinical Candidate for the Treatment of IBS.
AID431672Metabolic stability in rat liver microsome assessed as half life2009Journal of medicinal chemistry, Sep-10, Volume: 52, Issue:17
A multivalent approach to the design and discovery of orally efficacious 5-HT4 receptor agonists.
AID431673AUC (0 to t) in Sprague-Dawley rat at 5 mg/kg, po2009Journal of medicinal chemistry, Sep-10, Volume: 52, Issue:17
A multivalent approach to the design and discovery of orally efficacious 5-HT4 receptor agonists.
AID444052Hepatic clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID61855-hydroxytryptamine 4 receptor agonistic activity was measured by twitch response enhancing activity in electrically stimulated guinea pig ileum preparation1995Journal of medicinal chemistry, Jun-23, Volume: 38, Issue:13
The serotonin 5-HT4 receptor. 2. Structure-activity studies of the indole carbazimidamide class of agonists.
AID6386Tested for affinity towards 5-hydroxytryptamine 4 receptor in electrically stimulated longitudinal muscle preparation of guinea pig ileum2003Journal of medicinal chemistry, Jan-30, Volume: 46, Issue:3
5-HT4 receptor ligands: applications and new prospects.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID758758Binding affinity to serotonin 5-HT2A receptor (unknown origin)2013Bioorganic & medicinal chemistry letters, Jul-15, Volume: 23, Issue:14
Discovery of TD-8954, a clinical stage 5-HT(4) receptor agonist with gastrointestinal prokinetic properties.
AID431676Oral bioavailability in Sprague-Dawley rat at 5 mg/kg, po2009Journal of medicinal chemistry, Sep-10, Volume: 52, Issue:17
A multivalent approach to the design and discovery of orally efficacious 5-HT4 receptor agonists.
AID683466Agonist activity at 5HT4 receptor in guinea pig colonic longitudinal muscle/myenteric plexus assessed as contraction relative to 5HT2012Bioorganic & medicinal chemistry letters, Oct-01, Volume: 22, Issue:19
Discovery, oral pharmacokinetics and in vivo efficacy of velusetrag, a highly selective 5-HT(4) receptor agonist that has achieved proof-of-concept in patients with chronic idiopathic constipation.
AID684472Selectivity ratio of Ki for human 5HT3A receptor to Ki for human 5HT4c receptor2012Bioorganic & medicinal chemistry letters, Oct-01, Volume: 22, Issue:19
Discovery, oral pharmacokinetics and in vivo efficacy of velusetrag, a highly selective 5-HT(4) receptor agonist that has achieved proof-of-concept in patients with chronic idiopathic constipation.
AID672320Intrinsic activity at human 5HT4C receptor expressed in a cell line expressing receptor at 10 fold physiological-level assessed as cAMP accumulation relative to 5HT2012Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14
Discovery, oral pharmacokinetics and in vivo efficacy of a highly selective 5-HT4 receptor agonist: clinical compound TD-2749.
AID378830Displacement of [N-methyl-3H]GR-113808 from human 5HT4 receptor expressed in HEK293 cells2006Journal of natural products, Oct, Volume: 69, Issue:10
Brominated cyclodipeptides from the marine sponge Geodia barretti as selective 5-HT ligands.
AID683465Agonist activity at 5HT4 receptor in guinea pig colonic longitudinal muscle/myenteric plexus assessed as contraction2012Bioorganic & medicinal chemistry letters, Oct-01, Volume: 22, Issue:19
Discovery, oral pharmacokinetics and in vivo efficacy of velusetrag, a highly selective 5-HT(4) receptor agonist that has achieved proof-of-concept in patients with chronic idiopathic constipation.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID6723215-HT4C receptor-mediated exchange of GDP for europium labeled GTP (pEC50)2012Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14
Discovery, oral pharmacokinetics and in vivo efficacy of a highly selective 5-HT4 receptor agonist: clinical compound TD-2749.
AID758756Binding affinity to serotonin 5-HT7 receptor (unknown origin)2013Bioorganic & medicinal chemistry letters, Jul-15, Volume: 23, Issue:14
Discovery of TD-8954, a clinical stage 5-HT(4) receptor agonist with gastrointestinal prokinetic properties.
AID431671Permeability across human Caco-2 cells assessed as permeability coefficient2009Journal of medicinal chemistry, Sep-10, Volume: 52, Issue:17
A multivalent approach to the design and discovery of orally efficacious 5-HT4 receptor agonists.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID431693Oral bioavailability in human2009Journal of medicinal chemistry, Sep-10, Volume: 52, Issue:17
A multivalent approach to the design and discovery of orally efficacious 5-HT4 receptor agonists.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID444054Oral bioavailability in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID6723225-HT4C receptor-mediated exchange of GDP for europium labeled GTP (intrinsic activity)2012Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14
Discovery, oral pharmacokinetics and in vivo efficacy of a highly selective 5-HT4 receptor agonist: clinical compound TD-2749.
AID672174Selectivity ratio of Ki for human 5HT3A receptor to Ki for human 5HT4C receptor2012Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14
Discovery, oral pharmacokinetics and in vivo efficacy of a highly selective 5-HT4 receptor agonist: clinical compound TD-2749.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347412qHTS assay to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Counter screen cell viability and HiBit confirmation2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347081qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Confirmatory Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347088qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): Viability assay - Alamar blue signal for LCMV Confirmatory Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347084qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Confirmatory Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347087qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Confirmatory Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (319)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's12 (3.76)18.2507
2000's235 (73.67)29.6817
2010's52 (16.30)24.3611
2020's20 (6.27)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials68 (20.42%)5.53%
Reviews84 (25.23%)6.00%
Case Studies11 (3.30%)4.05%
Observational0 (0.00%)0.25%
Other170 (51.05%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (25)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Extension Study to Assess the Long-Term Safety of Tegaserod in Women With Symptoms of Dyspepsia[NCT00232102]Phase 3423 participants Interventional2004-09-30Completed
Assessment of the Role of Tegaserod Therapy in the Management of Gastroesophageal Reflux Disease (GERD) Symptoms in Patients With Incomplete Response to Proton Pump Inhibitors (PPIs).[NCT00171483]Phase 330 participants Interventional2004-01-31Completed
Assessment of Efficacy and Safety of Tegaserod Treatment and Placebo in Women With Dyspepsia[NCT00232089]Phase 31,296 participants Interventional2004-05-31Completed
Study of Effect of Tegaserod on Small and Large Bowel Transit by Scintigraphic Method[NCT00563615]60 participants (Anticipated)Interventional2004-11-30Recruiting
The Effect of Tegaserod on Patterns of Flow in the Small Bowel of Patients With Irritable Bowel Syndrome (IBS)[NCT00171431]Phase 320 participants Interventional2004-11-30Terminated(stopped due to This study was terminated early in May 2006 due to low patient enrollment)
The Effects of Tegaserod on Mechanical Sensitivity of the Esophagus and Stomach in Patients With Heartburn and Dyspepsia.[NCT00171457]Phase 324 participants Interventional2005-04-30Completed
Efficacy, Safety and Tolerability of Tegaserod in Patients With Chronic Constipation[NCT00149877]Phase 4250 participants Interventional2004-04-30Completed
A Treatment Investigational New Drug (tIND) Program of Tegaserod 6 mg Bid Given Orally in Women Adult Patients With Irritable Bowel Syndrome With Constipation or With Chronic Idiopathic Constipation[NCT00511771]0 participants Expanded AccessNo longer available
A Randomized, Double-blind, Placebo-controlled Multicenter Phase II/III Study to Evaluate the Efficacy and Safety of Tegaserod and Placebo Given Orally for 12 Weeks for the Treatment of Opioid-induced Constipation (OIC) in Patients With Chronic Non-cancer[NCT00365820]Phase 2/Phase 3670 participants Interventional2006-07-31Terminated(stopped due to This study was terminated early as a result of regulatory action suspending tegaserod use in 2007)
Assessment of Efficacy and Safety of Tegaserod Treatment and Placebo in Women With Dyspepsia[NCT00232024]Phase 31,296 participants Interventional2004-01-31Completed
A 52-week Extension to Study CHTF919N2201 to Evaluate the Safety and Efficacy of Tegaserod (6 mg b.i.d. and 12 mg o.d.) Given Orally for the Treatment of Opioid-induced Constipation (OIC) in Patients With Chronic Non-cancer Pain[NCT00399659]Phase 3360 participants (Actual)Interventional2006-11-30Terminated(stopped due to This study was terminated early as a result of regulatory action suspending tegaserod use in 2007)
Assessment of the Effect of Tegaserod (2 mg Tid and 6 mg Tid) on Dyspeptic Symptoms in Diabetic Patients With Symptoms of Diabetic Gastropathy[NCT00142974]Phase 2120 participants Interventional2004-05-31Terminated(stopped due to This study was terminated early in April 2005 due to low patient enrollment)
The Effects of Tegaserod on Orocecal Transit in Elderly Patients With Chronic Constipation[NCT00348634]Phase 460 participants (Anticipated)Interventional2006-07-31Terminated(stopped due to Terminated early due to regulatory action suspending tegaserod use in 2007)
An Evaluation of the Efficacy and Safety of Tegaserod 6 mg Bid Given Orally to Chinese Patients With Chronic Constipation[NCT00139568]Phase 3600 participants Interventional2005-02-28Completed
Assessment of Efficacy and Safety of Tegaserod in Male Patients With Chronic Constipation.[NCT00141089]Phase 31,026 participants Interventional2004-03-31Completed
A Randomized, Open-label, Pilot Crossover Study to Assess the Patient Preference of Tegaserod Versus Polyethylene Glycol 3350 in Patients With Constipation[NCT00171522]Phase 452 participants Interventional2005-05-31Completed
The Role of Tegaserod Therapy in the Management of Dyspeptic Symptoms in Female Patients on Proton Pump Inhibitors for the Treatment of Heartburn.[NCT00171470]Phase 360 participants Interventional2005-04-30Completed
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Assess the Efficacy, Safety and Tolerability of Tegaserod 2 mg Bid vs Placebo in Patients With Chronic Constipation[NCT00563758]250 participants (Actual)Interventional2004-12-31Terminated
An Open-label Pilot Trial to Assess the Effect of Tegaserod on Improvement of Gastric Emptying in Patients With Diabetic Gastroparesis and Upper Gastrointestinal Symptoms[NCT00390975]Phase 440 participants (Anticipated)Interventional2007-01-31Terminated(stopped due to This study was terminated early as a result of regulatory action suspending tegaserod use in 2007)
Efficacy of Tegaserod in Relieving the Symptoms of Female Patients With Irritable Bowel Syndrome (IBS), Excluding Those With Predominant Diarrhea IBS[NCT00142987]Phase 4664 participants Interventional2004-04-30Completed
A Study to Assess the Efficacy, Safety and Tolerability of Tegaserod Alone and in Combination With Omeprazole Given Orally in Patients With Symptoms of Symptomatic Gastroesophageal Reflux Disease (sGERD)[NCT00149851]Phase 2832 participants Interventional2004-01-31Completed
Assessment of the Effects of Tegaserod in the Management of Gastroesophageal Reflux Disease (GERD) in Patients With Incomplete Response to Proton Pump Inhibitors (PPIs).[NCT00171418]Phase 354 participants Interventional2003-06-30Completed
An Open Label 52-week Study to Evaluate the Safety and Efficacy of Tegaserod Given Orally for the Treatment of Opioid-induced Constipation (OIC) in Patients With Chronic Non-cancer Pain[NCT00414024]Phase 311 participants (Actual)Interventional2007-02-28Terminated(stopped due to This study was terminated early as a result of regulatory action suspending tegaserod use in 2007)
Extension Study to Assess the Long-Term Safety of Tegaserod in Women With Symptoms of Dyspepsia[NCT00232037]Phase 3359 participants Interventional2004-09-30Completed
A Randomized, Double-blind, Placebo-controlled Evaluation of the Effects of Tegaserod (6 mg b.i.d) on Whole Gut Transit Time in Patients With Chronic Idiopathic Constipation and Dyspepsia[NCT00277550]Phase 40 participants (Actual)InterventionalWithdrawn
[information is prepared from clinicaltrials.gov, extracted Sep-2024]